VivoSeq
Other

Hyponatremia

16

Pipeline Programs↗

2

Active Trials↗

13

Companies Involved↗

Hyponatremia is an emerging landscape with 16 programs across 13 companies. The most active players are Pfizer, Cumberland Pharmaceuticals, Sanofi. 3 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

62/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2C

Cumberland Pharmaceuticals

3 programs

Phase 3Sanofi logo

Sanofi

2 programs

Phase 3P

Palladio Biosciences

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Teva logo

Teva

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

39

clinical trials

Completed21 · 54%
Terminated10 · 26%
Withdrawn3 · 8%
Unknown status3 · 8%
Recruiting2 · 5%

Clinical Trials

Trial Activity

39 trials

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT04447911·172 enrolled
Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06020495·260 enrolled
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
Completed·CCumberland Pharmaceuticals·Phase 3·NCT00379847·251 enrolled
Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
Completed·—·N/A·NCT01850940·98 enrolled
The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.
Completed·—·N/A·NCT03371199·21 enrolled
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Completed·CCumberland Pharmaceuticals·Phase 3·NCT00380575·84 enrolled
Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia
Completed·IInstituto Tecnologico y de Estudios Superiores de Monterey·Phase 3·NCT01909336·161 enrolled
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia
Completed·CCardioKine Inc.·Phase 3·NCT00660959·106 enrolled
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Completed·Otsuka logoOtsuka·Phase 3·NCT03048747·16 enrolled
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
Completed·CCardioKine Inc.·Phase 3·NCT00578695·652 enrolled
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02729766·15 enrolled
Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS
Completed·TThomas Jefferson University·N/A·NCT01299779·460 enrolled
DILIPO (DILutIonal HyPOnatremia)
Completed·Sanofi logoSanofi·Phase 3·NCT00274326·150 enrolled
Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
Completed·CCumberland Pharmaceuticals·Phase 3·NCT00478192·50 enrolled
A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Completed·Otsuka logoOtsuka·Phase 2·NCT00664014·241 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)